Shares of ClearOne slid 7.7% to $5.51 on August 28 after investors weighed the full implications of a shareholder vote approving deeply discounted financing that could swell the company's share count by 20% or more, raising pointed questions about whether the cash raised will justify the ownership hit. ClearOne's Reverse-Merger Bet on Brain Implants Comes With a Brutal Ownership Haircut — Is the Neurostimulation Pivot Worth the Price?
ClearOne shares dropped 7.7% to $5.51 as investors absorbed the full cost of a shareholder-approved financing package and merger-related share issuance that will fundamentally reshape who owns this company. The vote clears the path for a reverse merger with Cortigent, a clinical-stage neurostimulation firm, but the math for existing shareholders is unforgiving.
• Existing Owners Are Being Diluted Into a Minority Stake. ClearOne agreed on July 1 to merge Cortigent — a Vivani Medical subsidiary developing precision neurostimulation implants — into a wholly owned subsidiary, with Vivani receiving 12.5 million new ClearOne shares.
The transaction will significantly dilute existing ClearOne shareholders, leaving them with an anticipated 12.7%–14.4% stake while Vivani holds 59.4%–67.5%. With only 2.68 million shares currently outstanding , issuing 12.5 million shares to Vivani alone represents nearly a five-fold expansion of the share count.
• The $10–$15 Million Financing Adds Another Layer of Dilution. Closing the deal requires a $10–$15 million equity financing , which shareholders just approved. ClearOne recently filed to sell up to 4.285 million units — each bundled with warrants — at what the company has described as a discount. On top of that, a new 2026 Omnibus Incentive Plan reserves 2.5 million shares for employee equity compensation. Combined, these pools make the dilution overhang enormous relative to the current tiny float.
• A 20-Day Waiting Period Keeps Uncertainty Alive. Stock issuance cannot take effect until 20 calendar days after ClearOne mails the Schedule 14C disclosure to shareholders , leaving the market in limbo about the exact timing and pricing of the financing. That uncertainty gap explains why shares have given back gains — the stock has fallen 22.2% over the past 12 months — even after brief merger-fueled rallies.
• The Strategic Gamble: From Empty-Shell Tech to Brain Implants. ClearOne's current business is essentially limited to fulfilling warranty obligations and liquidating remaining assets.
The Cortigent deal marks a strategic pivot from legacy communications toward high-risk, high-potential neurostimulation therapies, reshaping its operations and risk profile.
Vivani must lock up 50% of its shares for one year and the remainder for two years , offering some short-term stability — but the stock's current ~$15 million market capitalization prices in minimal confidence that a pre-revenue brain-implant company will deliver returns.
For existing shareholders, the question isn't whether this pivot is bold — it's whether owning roughly 13% of an unproven neurostimulation play justifies the wipeout.